🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07357779
Recruiting Not applicable

Clinical Efficacy and Health Economic Evaluation of an Intelligent Diagnostic and Treatment Model

NCT07357779 · tracked via the Priya Life Science China tracker
Sponsor
Zan Wang
Phase
Not applicable
Started
2026-01-20
Last updated
2026-07-10

Condition(s) studied

Insomnia

Investigational drug(s) / intervention(s)

Intelligent Diagnostic and Treatment ModelTraditional treatment

Intelligent Diagnostic and Treatment Model: Intelligent CBTI

Traditional treatment: sleep drug treatment

Study summary

The purpose of this study is to evaluate the clinical and cost-effectiveness of an intelligent therapy based on digital cognitive behavioral therapy for insomnia disorders

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * (1) Clinical diagnosis of insomnia disorder; (2) Cooperate to complete the questionnaire surveys. Exclusion Criteria: * (1) Current use of central nervous system stimulants; (2) Use of analgesics, theophylline preparations, steroid medications; (3) Alcohol abuse or regular alcohol intake; (4) Diagnosis of other sleep disorders (e.g., obstructive sleep apnea, rapid eye movement sleep behavior disorder, restless legs syndrome) ; (5) Sleep disorders secondary to organic diseases (e.g., epilepsy, diabetes, renal failure).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
the First Hospital of Jilin University Changchun Jilin Recruiting

More Zan Wang trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07357779 on ClinicalTrials.gov ↗ ← All trials in China